Elevated S100A4 expression leads to more malignant and aggressive phenotypes of tumor cells [41] and therefore is closely associated with poor outcome of human cancer patients, implying that targeting of S100A4 expression or activities may provide a novel strategy to combat metastatic cancer, improve prognosis and enhance survival of cancer patients. The gene discussed is S100A4; the disease is metastatic malignant neoplasm.